REACT

Disease site: Breast Cancer

Treatment Modality: Other

Status: Open to recruitment

It has long been recognised that there is an association between chronic immune activation and cancer but the mechanisms behind this observation are not fully understood (O’Byrne and Dalgleish, 2001). The inflammatory process may provide an environment for development of malignant disease, with mediators of inflammatory response such as the cyclo-oxygenases (COX) playing an important role and providing a target for therapeutic intervention.

There is evidence to suggest that COX-2 inhibitors could enhance the adjuvant treatment of breast cancer in inhibition of angiogenesis, cell growth, tumour-associated inflammation, invasion and promoting apoptosis.

The primary aim of the study is to assess the disease free survival (DFS) benefit of two years adjuvant therapy with celecoxib compared with placebo in primary breast cancer patients. The study requires randomisation of 2590 patients in total.
REACT is coordinated by the ICCG and the German Breast Group in collaboration with the ICR-CTSU and is run under the auspices of the Breast International Group. The study is part of the NIHR portfolio.